223 related articles for article (PubMed ID: 18442619)
1. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation.
Canibus P; Faloia E; Piva T; Muçai A; Serenelli M; Perna GP; Boscaro M; Piva R
Metabolism; 2008 May; 57(5):593-7. PubMed ID: 18442619
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications.
Qasim A; Cosgrave J; Latib A; Colombo A
Am J Cardiol; 2007 Dec; 100(11):1619-24. PubMed ID: 18036358
[TBL] [Abstract][Full Text] [Related]
3. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.
Bonello L; De Labriolle A; Lemesle G; Roy P; Steinberg DH; Slottow TL; Xue Z; Torguson R; Kaneshige K; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
Am J Cardiol; 2009 Feb; 103(4):496-500. PubMed ID: 19195509
[TBL] [Abstract][Full Text] [Related]
5. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation.
Zellweger MJ; Kaiser C; Brunner-La Rocca HP; Buser PT; Osswald S; Weiss P; Mueller-Brand J; Pfisterer ME;
J Nucl Med; 2008 Apr; 49(4):550-6. PubMed ID: 18344439
[TBL] [Abstract][Full Text] [Related]
6. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
Yan BP; Ajani AE; New G; Duffy SJ; Farouque O; Shaw J; Sebastian M; Lew R; Brennan A; Andrianopoulos N; Reid C; Clark DJ;
Int J Cardiol; 2008 Nov; 130(3):374-9. PubMed ID: 18706719
[TBL] [Abstract][Full Text] [Related]
7. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
8. Long term results of unprotected left main percutaneous coronary intervention with DES versus BMS.
Capodanno D; Di Salvo ME; Capranzano P; Seminara D; Caggegi A; Barrano G; Tamburino C
Minerva Cardioangiol; 2009 Feb; 57(1):1-6. PubMed ID: 19202514
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions.
Han YL; Zhang J; Li Y; Wang SL; Jing QM; Yi XH; Ma YY; Luan B; Wang G; Wang B
Chin Med J (Engl); 2009 Mar; 122(6):643-7. PubMed ID: 19323927
[TBL] [Abstract][Full Text] [Related]
10. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program.
Lasala JM; Cox DA; Morris DL; Breall JA; Mahoney PD; Horwitz PA; Shaw D; Hood KL; Mandinov L; Dawkins KD
Am J Cardiol; 2009 Jun; 103(12):1663-71. PubMed ID: 19539073
[TBL] [Abstract][Full Text] [Related]
11. Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials).
Garg P; Charytan DM; Novack L; Cutlip DE; Popma JJ; Moses J; Leon MB; Schofer J; Breithardt G; Schampaert E; Mauri L
Am J Cardiol; 2010 Nov; 106(10):1436-42. PubMed ID: 21059433
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
13. Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation.
Ota T; Umeda H; Yokota S; Miyata S; Takamura A; Sugino S; Hayashi K; Ishiki R; Takeichi Y; Iwase M; Inagaki H; Murohara T
Am Heart J; 2009 Jul; 158(1):92-8. PubMed ID: 19540397
[TBL] [Abstract][Full Text] [Related]
14. Impact of metabolic syndrome on clinical and angiographic outcome after sirolimus-eluting stent implantation.
Stellbrink E; Schröder J; Grawe A; Goebbels R; Blindt R; Kelm M; Hoffmann R
Coron Artery Dis; 2007 Dec; 18(8):601-6. PubMed ID: 18004109
[TBL] [Abstract][Full Text] [Related]
15. Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry).
Yan BP; Duffy SJ; Clark DJ; Lefkovits J; Warren R; Gurvitch R; Lew R; Sebastian M; Brennan A; Andrianopoulos N; Reid CM; Ajani AE;
Am J Cardiol; 2008 Jun; 101(12):1716-22. PubMed ID: 18549846
[TBL] [Abstract][Full Text] [Related]
16. Is adjunctive balloon postdilatation necessary with drug-eluting stents? One center experience in Chinese patients.
Gao Z; Yang YJ; Xu B; Chen JL; Qiao SB; Yao M; Chen J; Wu YJ; Liu HB; Dai J; Yuan JQ; Li JJ; Gao RL
Chin Med J (Engl); 2008 Mar; 121(6):513-7. PubMed ID: 18364137
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
20. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease.
Lee WL; Lee WJ; Chen YT; Liu TJ; Liang KW; Ting CT; Huey-Herng Sheu W
Metabolism; 2006 Aug; 55(8):1029-34. PubMed ID: 16839837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
